University of California Davis Comprehensive Cancer Center

Sacramento, CA

Sorting 6 by

Accepting patients

DREAMM12

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

KPG-818

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
Learn more
  • CELMoD
  • Phase 1

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3

Accepting patients

Dara-SVD vs. Dara-RVD

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
Learn more
  • SINE
  • Quadruplet Therapy
  • Phase 2

Accepting patients

BMF-219

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Learn more
  • Menin Inhibitor
  • Phase 1
2 hidden based on your filters. Show All